Atopic Dermatitis – Current State of Research on Biological Treatment

1 Yew YW, Thyssen JP, Silverberg JI. A systematic review and meta-analysis of the regional and age-related differences in atopic dermatitis clinical characteristics. J Am Acad Dermatol. 2019;80(2):390–401. doi: 10.1016/j.jaad.2018.09.035 YewYW ThyssenJP SilverbergJI A systematic review and meta-analysis of the regional and age-related differences in atopic dermatitis clinical characteristics J Am Acad Dermatol 2019 80 2 390 401 10.1016/j.jaad.2018.09.03530287309 Open DOISearch in Google Scholar

2 Roduit C, Frei R, Depner M, Karvonen AM, Renz H, Braun-Fahrländer C, et al. Phenotypes of atopic dermatitis depending on the timing of onset and progression in childhood. JAMA Pediatr. 2017;171(7):655–62. doi: 10.1001/jamapediatrics.2017.0556 RoduitC FreiR DepnerM KarvonenAM RenzH Braun-FahrländerC Phenotypes of atopic dermatitis depending on the timing of onset and progression in childhood JAMA Pediatr 2017 171 7 655 62 10.1001/jamapediatrics.2017.0556571033728531273 Open DOISearch in Google Scholar

3 Sybilski AJ, Raciborski F, Lipiec A, Tomaszewska A, Lusawa A, Samel-Kowalik P, et al. Atopic dermatitis is a serious health problem in Poland. Epidemiology studies based on the ECAP study. Postepy Dermatol Alergol. 2015;32(1):1–10. doi: 10.5114/pdia.2014.40935 SybilskiAJ RaciborskiF LipiecA TomaszewskaA LusawaA Samel-KowalikP Atopic dermatitis is a serious health problem in Poland. Epidemiology studies based on the ECAP study Postepy Dermatol Alergol 2015 32 1 1 10 10.5114/pdia.2014.40935436000025821420 Open DOISearch in Google Scholar

4 Rønnstad ATM, Halling-Overgaard AS, Hamann CR, Skov L, Egeberg A, Thyssen JP. Association of atopic dermatitis with depression, anxiety, and suicidal ideation in children and adults: a systematic review and meta-analysis. J Am Acad Dermatol. 2018;79(3):448–56.e30. doi: 10.1016/j.jaad.2018.03.017 RønnstadATM Halling-OvergaardAS HamannCR SkovL EgebergA ThyssenJP Association of atopic dermatitis with depression, anxiety, and suicidal ideation in children and adults: a systematic review and meta-analysis J Am Acad Dermatol 2018 79 3 448 56.e30 10.1016/j.jaad.2018.03.01730119868 Open DOISearch in Google Scholar

5 Yang EJ, Beck KM, Sekhon S, Bhutani T, Koo J. The impact of pediatric atopic dermatitis on families: a review. Pediatr Dermatol. 2019;36(1):66–71. doi: 10.1111/pde.13727 YangEJ BeckKM SekhonS BhutaniT KooJ The impact of pediatric atopic dermatitis on families: a review Pediatr Dermatol 2019 36 1 66 71 10.1111/pde.1372730556595 Open DOISearch in Google Scholar

6 Moyle M, Cevikbas F, Harden JL, Guttman-Yassky E. Understanding the immune landscape in atopic dermatitis: The era of biologics and emerging therapeutic approaches. Exp Dermatol. 2019;28(7):756–68. doi: 10.1111/exd.13911 MoyleM CevikbasF HardenJL Guttman-YasskyE Understanding the immune landscape in atopic dermatitis: The era of biologics and emerging therapeutic approaches Exp Dermatol 2019 28 7 756 68 10.1111/exd.13911685048030825336 Open DOISearch in Google Scholar

7 Suárez-Fariñas M, Dhingra N, Gittler J, Shemer A, Cardinale I, de Guzman Strong C, et al. Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis. J Allergy Clin Immunol. 2013;132(2):361–70. doi: 10.1016/j.jaci.2013.04.046 Suárez-FariñasM DhingraN GittlerJ ShemerA CardinaleI de Guzman StrongC Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis J Allergy Clin Immunol 2013 132 2 361 70 10.1016/j.jaci.2013.04.046399124023777851 Open DOISearch in Google Scholar

8 Osinka K, Dumycz K, Kwiek B, Feleszko W. Novel therapeutic approaches to atopic dermatitis. Arch Immunol Ther Exp (Warsz). 2018;66(3):171–81. doi: 10.1007/s00005-017-0487-1 OsinkaK DumyczK KwiekB FeleszkoW Novel therapeutic approaches to atopic dermatitis Arch Immunol Ther Exp (Warsz) 2018 66 3 171 81 10.1007/s00005-017-0487-128861617 Open DOISearch in Google Scholar

9 Brunner PM, Israel A, Zhang N, Leonard A, Wen HC, Huynh T, et al. Early-onset pediatric atopic dermatitis is characterized by T_H2/T_H17/T_H22-centered inflammation and lipid alterations. J Allergy Clin Immunol. 2018;141(6):2094–106. doi: 10.1016/j.jaci.2018.02.040 BrunnerPM IsraelA ZhangN LeonardA WenHC HuynhT Early-onset pediatric atopic dermatitis is characterized by T_H2/T_H17/T_H22-centered inflammation and lipid alterations J Allergy Clin Immunol 2018 141 6 2094 106 10.1016/j.jaci.2018.02.04029731129 Open DOISearch in Google Scholar

10 Nguyen HL, Anderson KR, Tollefson MM. New and emerging therapies for pediatric atopic dermatitis. Paediatr Drugs. 2019;21(4):239–60. doi: 10.1007/s40272-019-00342-w NguyenHL AndersonKR TollefsonMM New and emerging therapies for pediatric atopic dermatitis Paediatr Drugs 2019 21 4 239 60 10.1007/s40272-019-00342-w31364023 Open DOISearch in Google Scholar

11 Seo E, Yoon J, Jung S, Lee J, Lee BH, Yu J. Phenotypes of atopic dermatitis identified by cluster analysis in early childhood. J Dermatol. 2019;46(2):117–23. doi: 10.1111/1346-8138.14714 SeoE YoonJ JungS LeeJ LeeBH YuJ Phenotypes of atopic dermatitis identified by cluster analysis in early childhood J Dermatol 2019 46 2 117 23 10.1111/1346-8138.1471430520087 Open DOISearch in Google Scholar

12 Eyerich K, Novak N. Immunology of atopic eczema: overcoming the Th1/Th2 paradigm. Allergy. 2013;68(8):974–82. doi: 10.1111/all.12184 EyerichK NovakN Immunology of atopic eczema: overcoming the Th1/Th2 paradigm Allergy 2013 68 8 974 82 10.1111/all.1218423889510 Open DOISearch in Google Scholar

13 Glines KR, Stiff KM, Freeze M, Cline A, Stowd LC, Feldman SR. An update on the topical and oral therapy options for treating pediatric atopic dermatitis. Expert Opin Pharmacother. 2019;20(5):621–29. doi: 1.1080/14656566.2018.1561868 GlinesKR StiffKM FreezeM ClineA StowdLC FeldmanSR An update on the topical and oral therapy options for treating pediatric atopic dermatitis Expert Opin Pharmacother 2019 20 5 621 29 1.1080/14656566.2018.1561868 Open DOISearch in Google Scholar

14 Bos B, Antonescu I, Osinga H, Veenje S, de Jong K, de Vries TW. Corticosteroid phobia (corticophobia) in parents of young children with atopic dermatitis and their health care providers. Pediatr Dermatol. 2019;36(1):100–4. doi: 10.1111/pde.13698 BosB AntonescuI OsingaH VeenjeS de JongK de VriesTW Corticosteroid phobia (corticophobia) in parents of young children with atopic dermatitis and their health care providers Pediatr Dermatol 2019 36 1 100 4 10.1111/pde.1369830338542 Open DOISearch in Google Scholar

15 Alexander T, Maxim E, Cardwell LA, Chawla A, Feldman SR. Prescriptions for atopic dermatitis: oral corticosteroids remain commonplace. J Dermatolog Treat. 2018;29(3):238–40. doi: 10.1080/09546634.2017.1365112 AlexanderT MaximE CardwellLA ChawlaA FeldmanSR Prescriptions for atopic dermatitis: oral corticosteroids remain commonplace J Dermatolog Treat 2018 29 3 238 40 10.1080/09546634.2017.136511228789575 Open DOISearch in Google Scholar

16 Sarıcaoğlu H, Yazici S, Zorlu Ö, Bülbül Başkan E, Aydoğan K. Cyclosporine-A for severe childhood atopic dermatitis: clinical experience on efficacy and safety profile. Turk J Med Sci. 2018;48(5):933–8. doi: 10.3906/sag-1711-7 SarıcaoğluH YaziciS ZorluÖ Bülbül BaşkanE AydoğanK Cyclosporine-A for severe childhood atopic dermatitis: clinical experience on efficacy and safety profile Turk J Med Sci 2018 48 5 933 8 10.3906/sag-1711-730384556 Open DOISearch in Google Scholar

17 Taieb Y, Baum S, Ben Amitai D, Barzilai A, Greenberger S. The use of methotrexate for treating childhood atopic dermatitis: A multi-center retrospective study. J Dermatolog Treat. 2019;30(3):240–4. doi: 10.1080/09546634.2018.1508816 TaiebY BaumS Ben AmitaiD BarzilaiA GreenbergerS The use of methotrexate for treating childhood atopic dermatitis: A multi-center retrospective study J Dermatolog Treat 2019 30 3 240 4 10.1080/09546634.2018.150881630109960 Open DOISearch in Google Scholar

18 Klasa B, Cichocka-Jarosz E. Aktualne możliwości leczenia atopowego zapalenia skóry z perspektywy pediatry. The current possibilities of treatment for atopic dermatitis from pediatrician's perspective. Przegląd Lekarski. 2017;74(8):399–404. KlasaB Cichocka-JaroszE Aktualne możliwości leczenia atopowego zapalenia skóry z perspektywy pediatry The current possibilities of treatment for atopic dermatitis from pediatrician's perspective Przegląd Lekarski 2017 74 8 399 404 Search in Google Scholar

19 Brunner PM, Guttman-Yassky E, Leung DY. The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies. J Allergy Clin Immunol. 2017;139(4S):S65–76. doi: 10.1016/j.jaci.2017.01.011 BrunnerPM Guttman-YasskyE LeungDY The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies J Allergy Clin Immunol 2017 139 4S S65 76 10.1016/j.jaci.2017.01.011540570228390479 Open DOISearch in Google Scholar

20 Simpson EL, Flohr C, Eichenfield LF, Bieber T, Sofen H, Taïeb A, et al. Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: a randomized, placebo-controlled phase II trial (TREBLE). J Am Acad Dermatol. 2018;78(5):863.e11–71.e11. doi: 10.1016/j.jaad.2018.01.017 SimpsonEL FlohrC EichenfieldLF BieberT SofenH TaïebA Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: a randomized, placebo-controlled phase II trial (TREBLE) J Am Acad Dermatol 2018 78 5 863.e11 71.e11 10.1016/j.jaad.2018.01.01729353026 Open DOISearch in Google Scholar

21 Hamilton JD, Ungar B, Guttman-Yassky E. Drug evaluation review: dupilumab in atopic dermatitis. Immunotherapy. 2015;7(10):1043–58. doi: 10.2217/imt.15.69 HamiltonJD UngarB Guttman-YasskyE Drug evaluation review: dupilumab in atopic dermatitis Immunotherapy 2015 7 10 1043 58 10.2217/imt.15.6926598956 Open DOISearch in Google Scholar

22 Leung DY, Guttman-Yassky E. Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches. J Allergy Clin Immunol. 2014;134(4):769–79. doi: 10.1016/j.jaci.2014.08.008 LeungDY Guttman-YasskyE Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches J Allergy Clin Immunol 2014 134 4 769 79 10.1016/j.jaci.2014.08.008 Open DOISearch in Google Scholar

23 Danso MO, van Drongelen V, Mulder A, van Esch J, Scott H, van Smeden J, et al. TNF-α and Th2 cytokines induce atopic dermatitis-like features on epidermal differentiation proteins and stratum corneum lipids in human skin equivalents. J Invest Dermatol. 2014;134(7):1941–50. doi: 10.1038/jid.2014.83 DansoMO van DrongelenV MulderA van EschJ ScottH van SmedenJ TNF-α and Th2 cytokines induce atopic dermatitis-like features on epidermal differentiation proteins and stratum corneum lipids in human skin equivalents J Invest Dermatol 2014 134 7 1941 50 10.1038/jid.2014.83 Open DOISearch in Google Scholar

24 European Medicines Agency. 2018. Available from: https://www.ema.europa.eu/en/documents/pip-decision/p/0158/2018-ema-decision-15-june-2018-acceptance-modification-agreed-paediatric-investigation-plan_en.pdf. European Medicines Agency 2018 Available from: https://www.ema.europa.eu/en/documents/pip-decision/p/0158/2018-ema-decision-15-june-2018-acceptance-modification-agreed-paediatric-investigation-plan_en.pdf. Search in Google Scholar

25 REGENERON. FDA approves Dupixent® (dupilumab) for moderate-to-severe atopic dermatitis in adolescents. Tarrytown, NY, Cambridge, MA: PRNewswire. SOURCE Regeneron Pharmaceuticals, Inc.; 2019 March 11. Available from: https://newsroom.regeneron.com/news-releases/news-release-details/fda-approves-dupixentr-dupilumab-moderate-severe-atopic REGENERON FDA approves Dupixent® (dupilumab) for moderate-to-severe atopic dermatitis in adolescents Tarrytown, NY, Cambridge, MA PRNewswire. SOURCE Regeneron Pharmaceuticals, Inc. 2019 March 11 Available from: https://newsroom.regeneron.com/news-releases/news-release-details/fda-approves-dupixentr-dupilumab-moderate-severe-atopic Search in Google Scholar

26 Wollenberg A, Howell MD, Guttman-Yassky E, Silverberg JI, Kell C, Ranade K, et al. Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb. J Allergy Clin Immunol. 2019;143(1):135–41. doi: 10.1016/j.jaci.2018.05.029 WollenbergA HowellMD Guttman-YasskyE SilverbergJI KellC RanadeK Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb J Allergy Clin Immunol 2019 143 1 135 41 10.1016/j.jaci.2018.05.029 Open DOISearch in Google Scholar

27 Wenzel S, Wilbraham D, Fuller R, Getz EB, Longphre M. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet. 2007;370(9596):1422–31. doi: 10.1016/S0140-6736(07)61600-6 WenzelS WilbrahamD FullerR GetzEB LongphreM Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies Lancet 2007 370 9596 1422 31 10.1016/S0140-6736(07)61600-6 Open DOISearch in Google Scholar

28 Kunsleben N, Rüdrich U, Gehring M, Novak N, Kapp A, Raap U. IL-31 induces chemotaxis, calcium mobilization, release of reactive oxygen species, and CCL26 in eosinophils, which are capable to release IL-31. J Invest Dermatol. 2015;135(7):1908–11. doi: 10.1038/jid.2015.106 KunslebenN RüdrichU GehringM NovakN KappA RaapU IL-31 induces chemotaxis, calcium mobilization, release of reactive oxygen species, and CCL26 in eosinophils, which are capable to release IL-31 J Invest Dermatol 2015 135 7 1908 11 10.1038/jid.2015.10625789701 Open DOISearch in Google Scholar

29 Hänel KH, Pfaff CM, Cornelissen C, Amann PM, Marquardt Y, Czaja K, et al. Control of the physical and antimicrobial skin barrier by an IL-31-IL-1 signaling network. J Immunol. 2016;196(8):3233–44. doi: 10.4049/jimmunol.1402943 HänelKH PfaffCM CornelissenC AmannPM MarquardtY CzajaK Control of the physical and antimicrobial skin barrier by an IL-31-IL-1 signaling network J Immunol 2016 196 8 3233 44 10.4049/jimmunol.140294326944931 Open DOISearch in Google Scholar

30 Kabashima K, Furue M, Hanifin JM, Pulka G, Wollenberg A, Galus R, et al. Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study. J Allergy Clin Immunol. 2018;142(4):1121.e7–30.e7. doi: 10.1016/j.jaci.2018.03.018 KabashimaK FurueM HanifinJM PulkaG WollenbergA GalusR Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study J Allergy Clin Immunol 2018 142 4 1121.e7 30.e7 10.1016/j.jaci.2018.03.01829753033 Open DOISearch in Google Scholar

31 Shroff A, Guttman-Yassky E. Successful use of ustekinumab therapy in refractory severe atopic dermatitis. JAAD Case Rep. 2014;1(1):25–6. doi: 10.1016/j.jdcr.2014.10.007 ShroffA Guttman-YasskyE Successful use of ustekinumab therapy in refractory severe atopic dermatitis JAAD Case Rep 2014 1 1 25 6 10.1016/j.jdcr.2014.10.007480255327075132 Open DOISearch in Google Scholar

32 Guttman-Yassky E, Silverberg JI, Nemoto O, Forman SB, Wilke A, Prescilla R, et al. Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study. J Am Acad Dermatol. 2019;80(4):913.e9–21.e9. doi: 10.1016/j.jaad.2018.01.018 Guttman-YasskyE SilverbergJI NemotoO FormanSB WilkeA PrescillaR Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study J Am Acad Dermatol 2019 80 4 913.e9 21.e9 10.1016/j.jaad.2018.01.01829410014 Open DOISearch in Google Scholar

33 Guttman-Yassky E, Thaçi D, Pangan AL, Hong HC, Papp KA, Reich K, et al. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2020;145(3):877–84. doi: 10.1016/j.jaci.2019.11.025. Guttman-YasskyE ThaçiD PanganAL HongHC PappKA ReichK Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial J Allergy Clin Immunol 2020 145 3 877 84 10.1016/j.jaci.2019.11.025 31786154 Open DOISearch in Google Scholar

34 Gooderham MJ, Forman SB, Bissonnette R, Beebe JS, Zhang W, Banfield C, et al. Efficacy and safety of oral Janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: a phase 2 randomized clinical trial. JAMA Dermatol. 2019;155(12):1371–9. doi: 10.1001/jamadermatol.2019.2855 GooderhamMJ FormanSB BissonnetteR BeebeJS ZhangW BanfieldC Efficacy and safety of oral Janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: a phase 2 randomized clinical trial JAMA Dermatol 2019 155 12 1371 9 10.1001/jamadermatol.2019.2855677722631577341 Open DOISearch in Google Scholar

35 Kim BS, Howell MD, Sun K, Papp K, Nasir A, Kuligowski ME; INCB 18424-206 Study Investigators. Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream. J Allergy Clin Immunol. 2020;145(2):572–82. doi: 10.1016/j.jaci.2019.08.042 KimBS HowellMD SunK PappK NasirA KuligowskiME INCB 18424-206 Study Investigators Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream J Allergy Clin Immunol 2020 145 2 572 82 10.1016/j.jaci.2019.08.04231629805 Open DOISearch in Google Scholar

36 Bissonnette R, Maari C, Forman S, Bhatia N, Lee M, Fowler J, et al. The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled study. Br J Dermatol. 2019;181(4):733–42. doi: 10.1111/bjd.17932 BissonnetteR MaariC FormanS BhatiaN LeeM FowlerJ The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled study Br J Dermatol 2019 181 4 733 42 10.1111/bjd.17932685060530919407 Open DOISearch in Google Scholar

37 Nakagawa H, Nemoto O, Yamada H, Nagata T, Ninomiya N. Phase 1 studies to assess the safety, tolerability and pharmacokinetics of JTE-052 (a novel Janus kinase inhibitor) ointment in Japanese healthy volunteers and patients with atopic dermatitis. J Dermatol. 2018;45(6):701–9. doi: 10.1111/1346-8138.14322 NakagawaH NemotoO YamadaH NagataT NinomiyaN Phase 1 studies to assess the safety, tolerability and pharmacokinetics of JTE-052 (a novel Janus kinase inhibitor) ointment in Japanese healthy volunteers and patients with atopic dermatitis J Dermatol 2018 45 6 701 9 10.1111/1346-8138.14322600168729665062 Open DOISearch in Google Scholar

38 Paller AS, Tom WL, Lebwohl MG, Blumenthal RL, Boguniewicz M, Call RS, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol. 2016;75(3):494.e6–503.e6. doi: 10.1016/j.jaad.2016.05.046. Erratum in: J Am Acad Dermatol. 2017;76(4):777 PallerAS TomWL LebwohlMG BlumenthalRL BoguniewiczM CallRS Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults J Am Acad Dermatol 2016 75 3 494.e6 503.e6 10.1016/j.jaad.2016.05.046 Erratum in: J Am Acad Dermatol. 2017;76(4):777 27417017 Open DOISearch in Google Scholar

39 Ohba F, Nomoto M, Hojo S, Akama H. Safety, tolerability and pharmacokinetics of a novel phosphodiesterase inhibitor, E6005 ointment, in healthy volunteers and in patients with atopic dermatitis. J Dermatolog Treat. 2016;27(3):241–6. doi: 10.3109/09546634.2015.1093587 OhbaF NomotoM HojoS AkamaH Safety, tolerability and pharmacokinetics of a novel phosphodiesterase inhibitor, E6005 ointment, in healthy volunteers and in patients with atopic dermatitis J Dermatolog Treat 2016 27 3 241 6 10.3109/09546634.2015.109358726581111 Open DOISearch in Google Scholar

40 Czarnowicki T, He H, Krueger JG, Guttman-Yassky E. Atopic dermatitis endotypes and implications for targeted therapeutics. J Allergy Clin Immunol. 2019;143(1):1–11. doi: 10.1016/j.jaci.2018.10.032 CzarnowickiT HeH KruegerJG Guttman-YasskyE Atopic dermatitis endotypes and implications for targeted therapeutics J Allergy Clin Immunol 2019 143 1 1 11 10.1016/j.jaci.2018.10.03230612663 Open DOISearch in Google Scholar